J. Vekemans

发表

A phase 3 trial of RTS,S/AS01 malaria vaccine in African infants.

Kwaku Poku Asante, M. Tanner, K. Marsh, 2012, The New England journal of medicine.

Predicting RTS,S Vaccine-Mediated Protection from Transcriptomes in a Malaria-Challenge Clinical Trial

R. A. van den Berg, E. Jongert, J. Vekemans, 2017, Front. Immunol..

The respiratory syncytial virus vaccine landscape: lessons from the graveyard and promising candidates.

O. Ramilo, A. Mejias, R. Karron, 2018, The Lancet. Infectious diseases.

Meeting report: WHO consultation on Respiratory Syncytial Virus (RSV) vaccine development, Geneva, 25-26 April 2016.

R. Karron, J. Vekemans, D. Kaslow, 2017, Vaccine.

Plasmodium falciparum malaria vaccines in development

J. Vekemans, W. Ballou, Johan Vekemans, 2008, Expert review of vaccines.

Strain-specific Plasmodium falciparum growth inhibition among Malian children immunized with a blood-stage malaria vaccine

O. Doumbo, M. Thera, W. Blackwelder, 2017, PloS one.

Deficient IL-12(p35) Gene Expression by Dendritic Cells Derived from Neonatal Monocytes1

J. Vekemans, M. Goldman, P. Stordeur, 2001, The Journal of Immunology.

Tuberculosis vaccines: Rising opportunities

J. Vekemans, K. L. O'Brien, J. Farrar, 2019, PLoS medicine.

The way forward for tuberculosis vaccines.

Richard G. White, J. Vekemans, W. Hanekom, 2019, The Lancet. Respiratory medicine.

Maternal Trypanosoma cruzi Infection Upregulates Capacity of Uninfected Neonate Cells To Produce Pro- and Anti-Inflammatory Cytokines

J. Vekemans, Y. Carlier, C. Truyens, 2000, Infection and Immunity.

Safety and efficacy of the ChAdOx1 nCoV-19 vaccine (AZD1222) against SARS-CoV-2: an interim analysis of four randomised controlled trials in Brazil, South Africa, and the UK

Nguyen H. Tran, Vidyashankara G. Iyer, Andreas C. Themistocleous, 2020, Lancet.

Maternal Disease With Group B Streptococcus and Serotype Distribution Worldwide: Systematic Review and Meta-analyses

S. Madhi, S. Schrag, J. Lawn, 2017, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.

Stillbirth With Group B Streptococcus Disease Worldwide: Systematic Review and Meta-analyses

S. Madhi, Q. Bassat, S. Schrag, 2017, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.

Group B Streptococcal Disease Worldwide for Pregnant Women, Stillbirths, and Children: Why, What, and How to Undertake Estimates?

S. Madhi, S. Schrag, J. Lawn, 2017, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.

Preferred product characteristics for therapeutic vaccines to improve tuberculosis treatment outcomes: Key considerations from World Health Organization consultations.

J. Vekemans, M. Hatherill, M. Brennan, 2019, Vaccine.

Efficacy of RTS,S/AS01E vaccine against malaria in children 5 to 17 months of age.

M. Demoitié, K. Marsh, C. Drakeley, 2008, The New England journal of medicine.

Intrapartum Antibiotic Chemoprophylaxis Policies for the Prevention of Group B Streptococcal Disease Worldwide: Systematic Review

S. Madhi, S. Schrag, J. Lawn, 2017, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.

Effect of ingested human antibodies induced by RTS, S/AS01 malaria vaccination in children on Plasmodium falciparum oocyst formation and sporogony in mosquitoes

M. Fay, C. Drakeley, J. Lusingu, 2014, Malaria Journal.

Extended Safety, Immunogenicity and Efficacy of a Blood-Stage Malaria Vaccine in Malian Children: 24-Month Follow-Up of a Randomized, Double-Blinded Phase 2 Trial

O. Doumbo, M. Thera, W. Blackwelder, 2013, PloS one.

Safety and Immunogenicity of ChAd63/MVA Pfs25-IMX313 in a Phase I First-in-Human Trial

J. Vekemans, S. Faust, A. Lawrie, 2021, Frontiers in Immunology.

Strain-specific Plasmodium falciparum multifunctional CD4(+) T cell cytokine expression in Malian children immunized with the FMP2.1/AS02A vaccine candidate.

Andrea A. Berry, O. Doumbo, M. Thera, 2016, Vaccine.

WHO/IVI global stakeholder consultation on group A Streptococcus vaccine development: Report from a meeting held on 12-13 December 2016.

Jerome H. Kim, J. Vekemans, D. Kaslow, 2018, Vaccine.

Group B Streptococcus vaccine development: present status and future considerations, with emphasis on perspectives for low and middle income countries

S. Schrag, J. Vekemans, C. Baker, 2016, F1000Research.

Group B vaccine development : present status Streptococcus and future considerations , with emphasis on perspectives for low and middle income countries

S. Schrag, J. Vekemans, C. Baker, 2016 .

Circumsporozoite-Specific T Cell Responses in Children Vaccinated with RTS,S/AS01E and Protection against P falciparum Clinical Malaria

K. Marsh, A. Olotu, P. Bejon, 2011, PloS one.

Risk of Early-Onset Neonatal Group B Streptococcal Disease With Maternal Colonization Worldwide: Systematic Review and Meta-analyses

S. Madhi, S. Schrag, J. Lawn, 2017, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.

From the circumsporozoite protein to the RTS,S/AS candidate vaccine

V. Nussenzweig, Joe D. Cohen, A. Leach, 2010, Human vaccines.

Safety, Immunogenicity and Duration of Protection of the RTS,S/AS02D Malaria Vaccine: One Year Follow-Up of a Randomized Controlled Phase I/IIb Trial

Q. Bassat, J. Sacarlal, P. Aide, 2010, PloS one.

Randomized Controlled Trial of RTS,S/AS02D and RTS,S/AS01E Malaria Candidate Vaccines Given According to Different Schedules in Ghanaian Children

Kwaku Poku Asante, M. Demoitié, S. Owusu-Agyei, 2009, PloS one.

Vaccines for maternal immunization against Group B Streptococcus disease: WHO perspectives on case ascertainment and case definitions

S. Madhi, S. Schrag, J. Ordi, 2019, Vaccine.

Serocorrelates of protection against infant group B streptococcus disease.

S. Madhi, J. Vekemans, N. Andrews, 2019, The Lancet. Infectious diseases.

Molecular basis of allele-specific efficacy of a blood-stage malaria vaccine: vaccine development implications.

O. Doumbo, M. Thera, W. Blackwelder, 2013, The Journal of infectious diseases.

A field trial to assess a blood-stage malaria vaccine.

O. Doumbo, M. Thera, W. Blackwelder, 2011, The New England journal of medicine.

WHO consultation on group B Streptococcus vaccine development: Report from a meeting held on 27–28 April 2016

S. Madhi, S. Schrag, Peter G. Smith, 2016, Vaccine.

Research and development of new tuberculosis vaccines: a review [version 1; peer review: 3 approved, 1 approved with reservations]

J. Vekemans, R. Harris, L. Schrager, 2021 .

Vaccine impact on antimicrobial resistance to inform Gavi, the Vaccine Alliance’s 2018 Vaccine Investment Strategy: report from an expert survey

J. Vekemans, Sophie Mathewson, Wilson Mok, 2019, F1000Research.

Polarization of PPD-specific T-cell response of patients with tuberculosis from Th0 to Th1 profile after successful antimycobacterial therapy or in vitro conditioning with interferon-alpha or interleukin-12.

J. Vekemans, M. D’Elios, A. Marchant, 2001, American journal of respiratory cell and molecular biology.

Hepatitis B immunisation induces higher antibody and memory Th2 responses in new-borns than in adults.

H. Whittle, J. Vekemans, A. Marchant, 2004, Vaccine.

Neonatal Encephalopathy With Group B Streptococcal Disease Worldwide: Systematic Review, Investigator Group Datasets, and Meta-analysis

S. Madhi, S. Schrag, L. D. de Vries, 2017, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.

Infant Group B Streptococcal Disease Incidence and Serotypes Worldwide: Systematic Review and Meta-analyses

S. Madhi, Q. Bassat, S. Schrag, 2017, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.

Maternal immunization against Group B streptococcus: World Health Organization research and development technological roadmap and preferred product characteristics

S. Madhi, S. Schrag, J. Vekemans, 2018, Vaccine.

Induction of Plasmodium falciparum-Specific CD4+ T Cells and Memory B Cells in Gabonese Children Vaccinated with RTS,S/AS01E and RTS,S/AS02D

M. Demoitié, S. Agnandji, B. Lell, 2011, PloS one.

Malaria Vaccine of Tanzanian Children with the RTS,S/AS01 with NK Cell Responses after Immunization Antigen-Specific IL-2 Secretion Correlates

C. Drakeley, P. Bejon, Joe D. Cohen, 2012 .

Influence of Mycobacterium bovis Bacillus Calmette-Guérin on Antibody and Cytokine Responses to Human Neonatal Vaccination1

M. Newport, H. Whittle, J. Vekemans, 2002, The Journal of Immunology.

T cell responses to vaccines in infants: defective IFNγ production after oral polio vaccination

H. Whittle, J. Vekemans, A. Marchant, 2002, Clinical and experimental immunology.

Neonatal bacillus Calmette‐Guérin vaccination induces adult‐like IFN‐γ production by CD4+ T lymphocytes

M. Newport, J. Vekemans, M. D’Elios, 2001, European journal of immunology.

Responses to Human Neonatal Vaccination Calmette-Guérin on Antibody and Cytokine Bacillus bovis Mycobacterium Influence of

M. Newport, H. Whittle, J. Vekemans, 2001 .

Human vaccination against RH5 induces neutralizing antimalarial antibodies that inhibit RH5 invasion complex interactions.

Juliana K. Wambua, J. McCarthy, J. Vekemans, 2017, JCI insight.

Safety and efficacy of novel malaria vaccine regimens of RTS,S/AS01B alone, or with concomitant ChAd63-MVA-vectored vaccines expressing ME-TRAP

R. Sinden, G. Cooke, M. Lievens, 2018, npj Vaccines.

RTS,S malaria vaccine efficacy and immunogenicity during Plasmodium falciparum challenge is associated with HLA genotype

M. Lievens, J. Vekemans, C. Ockenhouse, 2018, Vaccine.

A Statistical Interaction between Circumsporozoite Protein-Specific T Cell and Antibody Responses and Risk of Clinical Malaria Episodes following Vaccination with RTS,S/AS01E

A. Olotu, P. Bejon, E. Jongert, 2012, PloS one.

Phase Ii, Randomized Trial to Assess the Safety and Immunogenicity of the Candidate Malaria Vaccines Rts,S/As02 and Rts,S/As01 When Given According to Different Vaccination Schedules in Children in Ghana

Kwaku Poku Asante, M. Demoitié, S. Owusu-Agyei, 2008 .

Immune Responses to the RTS,S/AS01 Malaria Vaccine Candidate: Lessons from Human Immunology, Parasitologic and Clinical Evaluations

J. Vekemans, 2017 .

Four year immunogenicity of the RTS,S/AS02(A) malaria vaccine in Mozambican children during a phase IIb trial.

Q. Bassat, M. Demoitié, J. Sacarlal, 2011, Vaccine.

Single-dose administration and the influence of the timing of the booster dose on immunogenicity and efficacy of ChAdOx1 nCoV-19 (AZD1222) vaccine: a pooled analysis of four randomised trials

Nguyen H. Tran, Vidyashankara G. Iyer, Andreas C. Themistocleous, 2021, The Lancet.

Group A Streptococcus Vaccines

Jerome H. Kim, J. Vekemans, L. Guilherme, 2021 .

Immune Responses to Mycobacterial Antigens in the Gambian Population: Implications for Vaccines and Immunodiagnostic Test Design

J. Vekemans, A. Marchant, K. McAdam, 2004, Infection and Immunity.

First results of phase 3 trial of RTS,S/AS01 malaria vaccine in African children.

Pedro Alonso, Trudie Lang, Bernhards Ogutu, 2011, The New England journal of medicine.

A Phase IIa Controlled Human Malaria Infection and Immunogenicity Study of RTS,S/AS01E and RTS,S/AS01B Delayed Fractional Dose Regimens in Malaria-Naive Adults

Linda A. Murray, N. Waters, E. Jongert, 2020, The Journal of infectious diseases.

Fractional Third and Fourth Dose of RTS,S/AS01 Malaria Candidate Vaccine: A Phase 2a Controlled Human Malaria Parasite Infection and Immunogenicity Study.

N. Waters, W. Robinson, W. Ballou, 2016, The Journal of infectious diseases.

Respiratory syncytial virus vaccine research and development: World Health Organization technological roadmap and preferred product characteristics.

R. Karron, Peter G. Smith, B. Graham, 2018, Vaccine.

Dissociation between tuberculin skin test and in vitro IFN-gamma responses following neonatal BCG vaccination.

M. Newport, J. Vekemans, A. Marchant, 2005, Journal of tropical pediatrics.

Leveraging Vaccines to Reduce Antibiotic Use and Prevent Antimicrobial Resistance: A World Health Organization Action Framework

G. Kang, M. Lipsitch, J. Vekemans, 2021, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.

Neonatal bacillus Calmette-Guérin vaccination induces adult-like IFN-gamma production by CD4+ T lymphocytes.

M. Newport, J. Vekemans, M. D’Elios, 2001, European journal of immunology.

malERA: An updated research agenda for diagnostics, drugs, vaccines, and vector control in malaria elimination and eradication

Robert W. Sauerwein, Ashley J. Birkett, Timothy N. C. Wells, 2017, PLoS medicine.

Safety of the RTS,S/AS02D candidate malaria vaccine in infants living in a highly endemic area of Mozambique: a double blind randomised controlled phase I/IIb trial

Q. Bassat, M. Demoitié, J. Sacarlal, 2007, The Lancet.

Safety and High Level Efficacy of the Combination Malaria Vaccine Regimen of RTS,S/AS01B With Chimpanzee Adenovirus 63 and Modified Vaccinia Ankara Vectored Vaccines Expressing ME-TRAP

R. Sinden, G. Cooke, M. Lievens, 2016, Journal of Infectious Diseases.

Estimates of the Burden of Group B Streptococcal Disease Worldwide for Pregnant Women, Stillbirths, and Children

S. Madhi, S. Schrag, S. Cousens, 2017, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.

Report from the World Health Organization’s third Product Development for Vaccines Advisory Committee (PDVAC) meeting, Geneva, 8–10th June 2016

J. Vekemans, D. Kaslow, B. Giersing, 2017, Vaccine.

Long-term immunogenicity and immune memory response to the hepatitis B antigen in the RTS,S/AS01E malaria vaccine in African children: a randomized trial

O. Traoré, S. Adjei, H. Tinto, 2020, Human Vaccines & Immunotherapeutics.

Safety and immunogenicity of RTS,S/AS01 malaria vaccine in infants and children with WHO stage 1 or 2 HIV disease: a randomised, double-blind, controlled trial.

M. Hamel, S. Kariuki, M. Oneko, 2016, The Lancet. Infectious diseases.

Maternal Colonization With Group B Streptococcus and Serotype Distribution Worldwide: Systematic Review and Meta-analyses

S. Madhi, Q. Bassat, S. Schrag, 2017, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.

35 – Malaria Vaccines

J. Vekemans, W. Ballou, 2018 .

Meeting report: WHO consultation on malaria vaccine development, Geneva, 15-16 July 2019.

P. Alonso, J. Vekemans, D. Schellenberg, 2021, Vaccine.

Safety and efficacy of novel malaria vaccine regimens of RTS,S/AS01B alone, or with concomitant ChAd63-MVA-vectored vaccines expressing ME-TRAP

R. Sinden, G. Cooke, M. Lievens, 2018, npj Vaccines.

Preterm Birth Associated With Group B Streptococcus Maternal Colonization Worldwide: Systematic Review and Meta-analyses

S. Madhi, S. Schrag, J. Lawn, 2017, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.

Correlates of protection against symptomatic and asymptomatic SARS-CoV-2 infection

J. Vekemans, P. Aley, M. Voysey, 2021, Nature Medicine.

Phase 1/2a Trial of Plasmodium vivax Malaria Vaccine Candidate VMP001/AS01B in Malaria-Naive Adults: Safety, Immunogenicity, and Efficacy

Joshua D. Hartzell, W. Ballou, Joe D. Cohen, 2016, PLoS neglected tropical diseases.

Safety and efficacy of the RTS,S/AS01E candidate malaria vaccine given with expanded-programme-on-immunisation vaccines: 19 month follow-up of a randomised, open-label, phase 2 trial.

Kwaku Poku Asante, M. Tanner, S. Agnandji, 2011, The Lancet. Infectious diseases.

Development of the RTS,S/AS Vaccine Candidate from Concept to Phase III

Joe D. Cohen, A. Leach, J. Vekemans, 2011 .

The effect of immunization schedule with the malaria vaccine candidate RTS,S/AS01E on protective efficacy and anti-circumsporozoite protein antibody avidity in African infants

Kwaku Poku Asante, M. Tanner, S. Agnandji, 2015, Malaria Journal.

Serological Evidence of Discrete Spatial Clusters of Plasmodium falciparum Parasites

K. Marsh, T. Theander, C. Drakeley, 2011, PloS one.

Efficacy of ChAdOx1 nCoV-19 (AZD1222) vaccine against SARS-CoV-2 variant of concern 202012/01 (B.1.1.7): an exploratory analysis of a randomised controlled trial

D. Bonsall, V. Libri, J. Vekemans, 2021, The Lancet.

Design of a phase III multicenter trial to evaluate the efficacy of the RTS,S/AS01 malaria vaccine in children across diverse transmission settings in Africa

Conor P. Cahill, E. Macete, S. Abdulla, 2011, Malaria Journal.

Antigen-Specific IL-2 Secretion Correlates with NK Cell Responses after Immunization of Tanzanian Children with the RTS,S/AS01 Malaria Vaccine

C. Drakeley, P. Bejon, J. Lusingu, 2012, The Journal of Immunology.

Neurodevelopmental Impairment in Children After Group B Streptococcal Disease Worldwide: Systematic Review and Meta-analyses

S. Madhi, S. Schrag, J. Lawn, 2017, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.

WHO preferred product characteristics for new vaccines against tuberculosis.

J. Vekemans, M. Hatherill, H. McShane, 2018, The Lancet. Infectious diseases.

Efficacy of ChAdOx1 nCoV-19 (AZD1222) Vaccine Against SARS-CoV-2 VOC 202012/01 (B.1.1.7)

D. Bonsall, V. Libri, J. Vekemans, 2021 .

Building momentum for malaria vaccine research and development: key considerations

P. Alonso, H. Tinto, P. Bejon, 2020, Malaria Journal.

Building momentum for malaria vaccine research and development: key considerations

H. Tinto, P. Bejon, J. Vekemans, 2020, Malaria Journal.

Phase Iib, Randomized, Double-Blind Trial to Assess the Efficacy, Safety and Immunogenicity of the Candidate Malaria Vaccine Rts,S/As01 in Kenyan and Tanzanian Children

M. Demoitié, K. Marsh, C. Drakeley, 2008 .

Safety and immunogenicity of RTS,S/AS02D malaria vaccine in infants.

M. Tanner, H. Mshinda, M. Demoitié, 2008, The New England journal of medicine.

Ad35.CS.01 - RTS,S/AS01 Heterologous Prime Boost Vaccine Efficacy against Sporozoite Challenge in Healthy Malaria-Naïve Adults

W. Ballou, Joe D. Cohen, E. Jongert, 2015, PloS one.

Effect of the Pre-erythrocytic Candidate Malaria Vaccine RTS,S/AS01E on Blood Stage Immunity in Young Children

K. Marsh, C. Drakeley, A. Olotu, 2011, The Journal of infectious diseases.

Efficacy of RTS,S/AS01E malaria vaccine and exploratory analysis on anti-circumsporozoite antibody titres and protection in children aged 5–17 months in Kenya and Tanzania: a randomised controlled trial

K. Marsh, C. Drakeley, A. Olotu, 2011, The Lancet. Infectious diseases.

Demonstration of the Blood-Stage Plasmodium falciparum Controlled Human Malaria Infection Model to Assess Efficacy of the P. falciparum Apical Membrane Antigen 1 Vaccine, FMP2.1/AS01.

J. McCarthy, N. Waters, G. Cooke, 2016, The Journal of infectious diseases.

Research and development of new tuberculosis vaccines: a review

J. Vekemans, R. Harris, L. Schrager, 2018, F1000Research.

Research and development of new tuberculosis vaccines: a review.

J. Vekemans, R. Harris, L. Schrager, 2018, F1000Research.

ChAdOx1 nCoV-19 (AZD1222) Vaccine in People Living With and Without HIV

S. Madhi, J. Vekemans, P. Moore, 2021 .

Development of the RTS,S/AS malaria candidate vaccine.

Joe D. Cohen, A. Leach, J. Vekemans, 2009, Vaccine.

The Path to Group A Streptococcus Vaccines: World Health Organization Research and Development Technology Roadmap and Preferred Product Characteristics

Jerome H. Kim, K. O'Brien, J. Carapetis, 2019, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.

HLA-B*35-restricted CD8 T cell epitopes in the antigen 85 complex of Mycobacterium tuberculosis.

A. King, G. Ogg, J. Vekemans, 2001, The Journal of infectious diseases.

Tuberculosis Contacts but Not Patients Have Higher Gamma Interferon Responses to ESAT-6 than Do Community Controls in The Gambia

J. Vekemans, P. Andersen, A. Marchant, 2001, Infection and Immunity.

Monophosphoryl Lipid A Activates Both Human Dendritic Cells and T Cells1

J. Vekemans, M. Goldman, Z. Amraoui, 2002, The Journal of Immunology.

Immune response to the hepatitis B antigen in the RTS,S/AS01 malaria vaccine, and co-administration with pneumococcal conjugate and rotavirus vaccines in African children: A randomized controlled trial

O. Traoré, S. Adjei, H. Tinto, 2018, Human vaccines & immunotherapeutics.

Evaluation of the safety and immunogenicity of the RTS,S/AS01E malaria candidate vaccine when integrated in the expanded program of immunization.

Kwaku Poku Asante, M. Tanner, M. Demoitié, 2010, The Journal of infectious diseases.

Efficacy of RTS,S/AS01E malaria vaccine administered according to different full, fractional, and delayed third or early fourth dose regimens in children aged 5–17 months in Ghana and Kenya: an open-label, phase 2b, randomised controlled trial

S. Adjei, M. Oneko, K. Otieno, 2022, The Lancet. Infectious diseases.

Safety and immunogenicity of the ChAdOx1 nCoV-19 (AZD1222) vaccine against SARS-CoV-2 in people living with and without HIV in South Africa: an interim analysis of a randomised, double-blind, placebo-controlled, phase 1B/2A trial

S. Madhi, J. Vekemans, P. Moore, 2021, The Lancet HIV.

A phase 2/3, participant-blind, observer-blind, randomised, controlled study to assess the safety and immunogenicity of SII-ChAdOx1 nCoV-19 (COVID-19 vaccine) in adults in India

N. Gogtay, J. Vekemans, S. Panda, 2021, EClinicalMedicine.

The Development of the Adjuvant System AS01: A Combination of Two Immunostimulants MPL and QS-21 in Liposomes

J. Vekemans, A. Didierlaurent, N. Garçon, 2017 .

Immunogenicity and safety of AZD1222 (ChAdOx1 nCoV-19) against SARS-CoV-2 in Japan: a double-blind, randomized controlled phase 1/2 trial

J. Vekemans, Erika Yoshida, U. Olsson, 2021, International Journal of Infectious Diseases.

Avidity of Anti-Circumsporozoite Antibodies following Vaccination with RTS,S/AS01E in Young Children

K. Marsh, A. Olotu, P. Njuguna, 2014, PloS one.

The Gambia to ESAT-6 than Do Community Controls in Have Higher Gamma Interferon Responses Tuberculosis Contacts but Not Patients

J. Vekemans, A. Marchant, K. McAdam, 2000 .

Potential effect of age of BCG vaccination on global paediatric tuberculosis mortality: a modelling study

Richard G. White, J. Vekemans, C. Sanderson, 2019, The Lancet. Global health.

The role of immune correlates of protection on the pathway to licensure, policy decision and use of group B Streptococcus vaccines for maternal immunization: considerations from World Health Organization consultations

S. Madhi, S. Schrag, Peter G. Smith, 2019, Vaccine.

Assessment of severe malaria in a multicenter, phase III, RTS, S/AS01 malaria candidate vaccine trial: case definition, standardization of data collection and patient care

Kwaku Poku Asante, K. Marsh, J. Sacarlal, 2011, Malaria Journal.

Randomized, controlled trial of the long term safety, immunogenicity and efficacy of RTS,S/AS02D malaria vaccine in infants living in a malaria-endemic region

M. Tanner, H. Mshinda, S. Abdulla, 2013, Malaria Journal.

Safety and High Level Efficacy of the Combination Malaria Vaccine Regimen of RTS,S/AS01B with ChAd-MVA Vectored Vaccines Expressing ME-TRAP

R. Sinden, G. Cooke, M. Lievens, 2016 .

Delay in motor development of twins in Africa: a prospective cohort study.

M. Newport, H. Weiss, J. Vekemans, 2003, Twin research : the official journal of the International Society for Twin Studies.

The case for assessing the full value of new tuberculosis vaccines

J. Vekemans, S. den Boon, M. Zignol, 2020, European Respiratory Journal.

The March Toward Malaria Vaccines.

S. Hoffman, J. Vekemans, T. Richie, 2015, American journal of preventive medicine.

T Cell Responses to the RTS,S/AS01E and RTS,S/AS02D Malaria Candidate Vaccines Administered According to Different Schedules to Ghanaian Children

Kwaku Poku Asante, S. Owusu-Agyei, D. Dosoo, 2011, PloS one.

The march toward malaria vaccines.

S. Hoffman, J. Vekemans, T. Richie, 2015, Vaccine.

[The malaria vaccine candidate RTS,S/AS is in phase III clinical trials].

A. Leach, J. Vekemans, J. Cohen, 2010, Annales pharmaceutiques francaises.

The complex challenges of HIV vaccine development require renewed and expanded global commitment

Maureen M Goodenow, Jerome H. Kim, T. Ndung’u, 2019, The Lancet.

Template protocol for clinical trials investigating vaccines--focus on safety elements.

Robert T. Chen, S. Kochhar, D. Nalin, 2013, Vaccine.

Measuring indirect transmission-reducing effects in tuberculosis vaccine efficacy trials: why and how?

Richard G. White, J. Vekemans, W. Hanekom, 2023, The Lancet. Microbe.

Long-term safety and efficacy of the RTS,S/AS02A malaria vaccine in Mozambican children.

Inácio Mandomando, Marie-Claude Dubois, Quique Bassat, 2009, The Journal of infectious diseases.

Safety of the Malaria Vaccine Candidate, RTS,S/AS01E in 5 to 17 Month Old Kenyan and Tanzanian Children

K. Marsh, C. Drakeley, A. Olotu, 2010, PloS one.

A Randomized Trial Assessing the Safety and Immunogenicity of AS01 and AS02 Adjuvanted RTS,S Malaria Vaccine Candidates in Children in Gabon

M. Demoitié, S. Agnandji, B. Lell, 2009, PloS one.

Pooled analysis of safety data from pediatric Phase II RTS,S/AS malaria candidate vaccine trials

Yolanda Guerra, D. Lapierre, A. Leach, 2011, Human vaccines.

Report from the World Health Organization’s third Product Development for Vaccines Advisory Committee (PDVAC) meeting, Geneva, 8–10th June 2016

J. Vekemans, D. Kaslow, B. Giersing, 2017, Vaccine.

Efficacy of RTS,S/AS01E vaccine against malaria in children 5 to 17 months of age.

M. Demoitié, K. Marsh, A. Olotu, 2008, The New England journal of medicine.

The respiratory syncytial virus vaccine landscape: lessons from the graveyard and promising candidates.

O. Ramilo, A. Mejias, R. Karron, 2018, The Lancet. Infectious diseases.

Major Global Vaccine Challenges: Recent Progress in Malaria Vaccine Development

J. Vekemans, 2016 .

HIV immunoprophylaxis: preparing the pathway from proof of concept to policy decision and use.

H. Rees, J. Vekemans, D. Kaslow, 2019, The lancet. HIV.

Efficacy of ChAdOx1 nCoV-19 (AZD1222) vaccine against SARS-CoV-2 variant of concern 202012/01 (B.1.1.7): an exploratory analysis of a randomised controlled trial

D. Bonsall, V. Libri, J. Vekemans, 2021, The Lancet.

Ad35.CS.01 - RTS,S/AS01 Heterologous Prime Boost Vaccine Efficacy against Sporozoite Challenge in Healthy Malaria-Naïve Adults

W. Ballou, E. Jongert, M. Lievens, 2015, PloS one.